期刊文献+

VEGF受体KDR克隆及其对内皮细胞增殖和血管新生的影响 被引量:3

Cloning of cDNA Encoding Extra-Cellular Domain of Human VEGF Receptor KDR and Effect of Its Recombinant Protein on Endothelial Cell Proliferation and Angiogenesis
暂未订购
导出
摘要 目的 :克隆VEGF受体KDR基因膜外 5 7区 ,探讨其生物学活性。方法 :提取脐静脉血管内皮细胞总RNA ,克隆KDR基因膜外部分 5 7区 ,并使之在QIA表达系统进行表达 ;镍柱亲和层析纯化、复性、生物学活性鉴定。结果 :该系统能表达KDR基因片段 ,表达量约占菌体蛋白总量的 5 %左右。经复性 ,可溶性蛋白具有与VEGF特异结合功能 ,并能抑制VEGF促使脐静脉内皮细胞增殖和鸡胚绒毛尿囊膜血管生成的作用。结论 :KDR基因片段能在QIA表达系统中得到表达 ,复性后表达蛋白具有与VEGF结合的生物学功能。 Objective: To clone cDNA encoding Ⅴ-Ⅶ extra-cellular domains of VEGF receptor KDR and investigate biological activity of the recombinant protein. Methods: Total RNA from the umbelical venous endothelial cells was obteined. From it, KDR cDNA was cloned into the BamH1 and Kpn 1 sites of pQE31 and made expressed with induction of IPTG. The recombinant protein was purified, refolded and determined for its biological activities. Results: The expression system could express the human recombinant extra-cellular protein of KDR with expression level accounting for 5% of the total bacterial protein. After renaturation, the recombinant protein could bind to 125 I-VEGF and suppress endothelial cell proliferation and angiogenesis of chick chorioallantoic membrance induced by VEGF. Conclusion: Human KDR extra-cellular domain can be expressed in E coli and after being refolded, has an action of binding to VEGF.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2001年第3期173-177,共5页 Chinese Journal of Cancer Biotherapy
基金 上海市卫生局课题资金资助 ( 992 4)
关键词 血管内皮细胞生长因子 可溶性受体 KDR 原核表达 Pichia酵母 血管新生 内皮细胞增殖 肿瘤 vascular endothelial growth factor soluble receptor KDR procaryotic expression pichia yeast angiogenesis
  • 相关文献

参考文献1

二级参考文献2

  • 1Kim K J,Nature,1993年,362卷,842页
  • 2杨小平,中华心血管病杂志,1988年,16卷,298页

共引文献5

同被引文献12

  • 1徐承熊 韩锐.MTT法测定药物对癌细胞杀伤作用的选择.抗癌药物研究与实验技术[M].北京:北京医科大学和协和大学出版社,1997.284-286.
  • 2杨小平 陈国芬 等.人脐静脉内皮细胞培养及形态观察[J].中华心血管病杂志,1988,16:288-300.
  • 3Ettomger DS. Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer[J]. The Oncologist,2002,7: 226
  • 4O'Reilly MS,Holmgren L,Shing Y,et al. Angiostatin:a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [J]. Cell, 1994,79:315
  • 5Herbst RS,Hidalgo M,Pierson AS,et al. Angiogenesis inhibitors in clinical development for lung cancer [J]. Semin Oncol,2002,29(s4) :6
  • 6O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice [J]. Nat Med, 1996,2:689
  • 7Te Velde EA, Vogten JM, Gebbink MF, et al. Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model [J]. Br J Surg,2002,89(10) :1302
  • 8Teicher BA, Holden Sa,Ara C,et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents [J]. Int J Cancer, 1994 ; 57: 920
  • 9Teicher BA,Dupuis NP,Robinson M,et al. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing lewis lung carcinoma[J]. Oncol Res, 1995,7: 237
  • 10Gorski DH, Mauceri HJ, Salloum RM, et al. Potentiation of the anticancer effect of ionizing radiation by brief concomitant exposures to angiostatin[J]. Cancer Res, 1998,58 : 5686

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部